Baseline predictions of PACC progression trajectories in preclinical AD improve the precision and power of treatment effect assessments

Abstract

Background: Variability in cognitive decline in preclinical Alzheimer’s disease (AD) presents a significant challenge in evaluating treatment effects in clinical trials. This study developed models to forecast cognitive progression and assessed their potential to improve the precision of treatment effect estimates in future trials.

The paper